Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...

Diversified healthcare company CVS Health (NYSE:CVS) announced better-than-expected revenue in Q1 CY2025, with sales up 7% ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

The common theme at the maker of Wegovy and at UnitedHealth may be investors' sudden awareness of cost-cutting pressure.

It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

"The Novo Nordisk Foundation is increasing its influence and has appointed its chairman, Lars Rebien Sørensen, as an observer ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut with the company, along with Novo ...